Antonio Benedetti appointed as CEO of Cycle Pharmaceuticals

JANUARY 11, 2016
Cycle Pharmaceuticals (Cycle) announced today the appointment of Antonio Benedetti as CEO, effective immediately.
James Harrison becomes the Executive Chairman of Cycle and Bill Robinson becomes the non-executive Deputy Chairman of Cycle.

Mr Benedetti joins Cycle from Magirus where he was CEO. Magirus is a global leading fire engine company. Since 1864, Magirus has stood for innovation and tradition for firefighters around the world, providing comprehensive state-of-the-art fire trucks, ladders, rescue and equipment vehicles. Magirus is one of the largest technology leaders in the firefighting industry. With more than 1,300 employees and operations in Germany, Austria, Italy and France, Magirus is present in more than 100 countries and in the last years has been through an intensive turnaround which involved Industrial footprint, operations, product portfolio renewal, global expansion and brand repositioning.

Prior to Magirus, Mr Benedetti was Group CFO and Director of Archimica, an international contract manufacturing organisation of active pharmaceutical ingredients and their pre-cursors for the global branded and generic pharmaceutical industries. Prior to Archimica, Mr Benedetti worked for more than 10 years in different sectors of the Fiat Group, including Case New Holland, Fiat Powertrain Technologies and Fiat Group Automobiles.

Mr Benedetti brings a broad and international experience in global business expansion.

James Harrison, Executive Chairman of Cycle Pharmaceuticals commented:

Antonio is a highly talented leader and has been recognised as such within the Fiat Group. Antonio brings significant and varied industrial and business growth experience to Cycle, an international mind-set, and a track-record of delivery that has been proven in the automotive and pharmaceutical industries over many years. Hiring a leader of Antonio’s calibre is a great endorsement of Cycle’s differentiated business model to improve existing pharmaceuticals for the benefit of patients around the world. I look forward to working with him as he leads the growth of our business.

About Cycle Pharmaceuticals

Cycle Pharmaceuticals is a Cambridge-based pharmaceutical company that optimises and increases access to existing pharmaceuticals. Specifically, Cycle focuses on three areas of pharmaceutical development:

  • Improving orphan drugs, which treat the under-served rare disease patient community;
  • Reinstating drug products that have been previously marketed;
  • Working with our academic and other partners to extend pharmaceuticals to new medical areas where there is clear unmet need.

For further information, please visit www.cyclepharma.com.